BioMarin Pharmaceutical has announced results from its Phase II multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral arterial disease. There was no statistical
This technology is based on the findings of a study led by Jean-Claude Tardif at the Montreal Heart Institute research center in Canada. In Dr Tardif’s placebo-controlled study
Most recently, Mr Sneider served as CFO of NimbleGen Systems. Prior to NimbleGen, Mr Sneider was CFO of Third Wave Technologies. Mr Sneider holds a BBA and JD
The new dosing strengths, 45mg and 75mg, complement the currently available 30mg, 60mg, 90mg and 120mg dosages. Avinza is a long-acting opioid for patients with moderate to severe
The new offices located in Kiev and Bratislava will support staff in Ukraine and Slovakia, including Covance’s regional network of field-based clinical research associates throughout central and eastern
Lamotrigine chewable tablets, marketed by GlaxoSmithKline as Lamictal chewable dispersible tablets, is a prescription pharmaceutical product used in treating seizures. Taro previously filed a ‘Paragraph IV’ certification challenging
ESBATech, a developer of antibody fragment therapeutics, has initiated a Phase Ib/IIa study in patients undergoing cataract surgery. This study is designed to evaluate the safety, tolerability, and
Approximately 240 of these reductions are corporate positions associated with synergies from the Alpharma acquisition. Approximately 520 of these reductions are associated with the restructuring announced earlier, of
Merck has reported a net income of $1.64 billion, or $0.78 per diluted share, for the fourth quarter of 2008, compared to a net loss of $1.63 billion,
Under the terms of the merger agreement, JLL will commence a tender offer to purchase all of the outstanding shares of PharmaNet at a price of $5 per
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.